Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis

BACKGROUND: The objective of this analysis was to evaluate the cost-effectiveness of using bendamustine versus alemtuzumab or bendamustine versus chlorambucil as a first-line therapy in patients with Binet stage B or C chronic lymphocytic leukemia (CLL) in the US. METHODS: A discrete event simulatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Kongnakorn, Thitima, Sterchele, James A, Salvador, Christopher G, Getsios, Denis, Mwamburi, Mkaya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979694/
https://www.ncbi.nlm.nih.gov/pubmed/24729719
http://dx.doi.org/10.2147/CEOR.S55095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979694/
https://www.ncbi.nlm.nih.gov/pubmed/24729719
http://dx.doi.org/10.2147/CEOR.S55095

Ejemplares similares